TABLE 3.

P. falciparum in vitro growth-accelerating activity of anti-RAP-1_23–711 MAbs^a

MAb(s) (concn [μg/ml])	% Inhibitionb	95% CIc
RAP1-7 (350)	−47.1	−106–−4.9
RAP1-7 (500)	−34.3	−52.9–−17.9
RAP1-8 (500)	−22.9	−54.4–2.2
RAP1-14 (350)	−15.5	−78–25
RAP1-14 (500)	1.1	−7.4–8.9
RAP1-7 + RAP1-14 (350)d	−64.7	−123.1–−21.6
RAP2-16 (500)	−44.5	−77.9–−17.4
RAP5-2 (100)	−6.3	−41.4–20.1
RAP5-2 (200)	−19.3	−59.5–10.7
RAP5-2 (300)	−26.3	−51.9–−4.6
RAP5-2 (400)	−35.9	−66.1–−11.2
RAP5-2 (500)	−21.2	−46.9–0.2

^aSchizont stage parasites were plated in sextuplicate at initial parasitemia values of 0.5%. After 96 h the final parasitemia was determined by flow cytometry. 

^bLinear parasitemia values were transformed into logarithmic scale, and the mean was determined. Percent inhibition was calculated as follows: 100 × [1 − (geometric sample mean)/(geometric control mean)]. 

^cP < 0.05 by two-sided t test. Confidence intervals (CI) were calculated by antilogging the confidence limits calculated on the log scale. 

^dBoth MAbs were at the same concentration.